Outcomes of People of Color in an Efficacy Trial of Cognitive-Behavioral Treatments for Anxiety, Depression, and Related Disorders

Preliminary Evidence

Nicole D. Cardona, MA,* Amantia A. Ametaj, PhD,† Clair Cassiello-Robbins, PhD,‡
Julianne Wilner Tirpak, PhD,§|| Olenka Olesnycky, MA,¶ Shannon Sauer-Zavala, PhD,#
Todd J. Farchione, PhD,* and David H. Barlow, PhD*

Abstract: Although evidence-based psychological treatments such as cognitive behavioral therapy (CBT) have strong empirical support for reducing anxiety and depression symptoms, CBT outcome research often does not report race and ethnicity variables, or assess how well CBT works for people from historically excluded racial and ethnic groups. This study presents post hoc analyses comparing treatment retention and symptom outcomes for participants of color ($n = 43$) and White participants ($n = 136$) from a randomized controlled efficacy trial of CBT. χ^2 tests and one-way ANCOVA showed no observable differences between the two samples on attrition or on clinician-rated measures of anxiety and depression at posttreatment and follow-up. Moderate to large within-group effect sizes on anxiety and depression were found for Black, Latinx, and Asian American participants at almost all time points. These preliminary findings suggest that CBT for anxiety and comorbid depression may be efficacious for Black, Asian American, and Latinx individuals.

Key Words: People of color, cognitive behavioral therapy, treatment outcomes, race, ethnicity

(J Nerv Ment Dis 2023;211: 711–720)

Evidence-based psychological treatments (EBPTs) are the criterion standard of care for common mental health conditions, such as anxiety, depressive, and related disorders (David et al., 2018; Rachman, 2009). However, empirical support is still being established for several EBPTs (*e.g.*, cognitive behavioral therapy (CBT), behavior activation, mindfulness-based interventions) with racially and ethnically marginalized adults (Huey et al., 2014), or "people of color (POC)." In accordance with guidelines from National Institutes of Health (NIH, 2001), POC in this article includes individuals identifying as (1) any race other than White, (2) ethnically Latinx, or (3) more than one race. Historically, Black, Indigenous, Asian American, and Latinx individuals have not been adequately represented in clinical trials (Geller et al., 2011), and the consequence of White participants being overrepresented in clinical trials is that there is insufficient empirical evidence for the efficacy of standard EBPTs for POC.

In 1993, the NIH Revitalization Act passed by the US Congress mandated inclusion of underrepresented groups (National Institutes of Health, 1993), such as Black, Latinx, and Indigenous people, into clinical research. Eight years later, a US Surgeon General report on mental health care highlighted that no clear guidelines for treating mental health in POC could be determined given the scarcity of research in this area (US Department of Health and Human Services, 2001), and NIH issued a policy mandating the inclusion of POC in NIH-funded clinical research (NIH, 2001). Despite these mandates and other calls to action, reported numbers of POC in clinical trials for mental health treatments remain low (Benuto et al., 2020; DeLuca et al., 2018; Grau et al., 2022; Mendoza et al., 2012; Polo et al., 2019). For example, Benuto et al. (2020) conducted a systematic review of POC participants in clinical trials of prolonged exposure therapy for the treatment of posttraumatic stress disorder (PTSD) and found that although Black/African American individuals were overrepresented in many studies, only 4.9% of participants were Latinx and 0.6% were Asian American or Pacific Islander, with 4.7% selecting "other." Demographic information on race and ethnicity of treatment samples is still frequently omitted (Geller et al., 2018; Polo et al., 2019), and even when race and ethnicity are reported, few researchers examine outcomes of POC specifically (Geller et al., 2011). Consequently, NIH issued an amendment to the original mandate requiring analyses by race and ethnicity as well as "sex/gender" (NIH, 2017). As most EBPTs were developed and tested in academic institutions with predominantly White faculty and students, and thus reflect the needs and values of White patient populations (which may vary from other groups), the question remains as to whether POC improve when they receive standard EBPTs, and whether improvements occur at similar rates in comparison to White patients.

The question of whether standard EBPTs are efficacious for POC is important for efficient identification of treatment options for members of these marginalized racial and ethnic groups, which is needed as part of the effort to meet the growing demand for services. Empirical support for standard EBPTs delivered to POC is a critical public health need as these patients comprise a growing portion of the US population (Vespa et al., 2018). Unfortunately, mental health service use disparities for POC compared with White individuals have endured (De Luca et al., 2016), with Asian Americans seeking care at particularly low rates (Cook et al., 2014; Lipson et al., 2018; Yang et al., 2020). Research has shown that mismatches between interventions and patients, including low cultural sensitivity of treatments or providers, may lead to lower treatment engagement, irregular attendance, and limited overall effectiveness of care (Whaley and Davis, 2007). If standard EBPTs fail to produce equitable benefits for POC and White patients (*i.e.*, if POCs who do access treatment are systematically not improving at the same rate or to the same degree as White patients), it suggests that standard EBPTs may not be adequate for these patients (Huey et al., 2014; Sbrocco et al., 2005). As such, to avoid the negative effects of ineffective treatment, it is important to advance knowledge on standard EBPTs for POC.

*Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts; †Department of Epidemiology, Harvard Chan School of Public Health, Boston, Massachusetts; ‡Triangle Area Psychology Clinic, Durham, North Carolina; §McLean Hospital, Belmont, Massachusetts; ||Harvard Medical School, Boston, Massachusetts; ¶Department of Psychology, Hofstra University, Hempstead, New York; and #Department of Psychology, University of Kentucky, Lexington, Kentucky.
Send reprint requests to Nicole D. Cardona, MA, 900 Commonwealth Ave, 2nd Fl, Boston, MA 02215. E-mail: ncardona523@gmail.com.

Empirical support for EBPTs from the last two decades continues to be limited for POC in both scope and scientific rigor (*e.g.*, naturalistic studies that lack control groups) (Carter and Sbrocco, 2018; Horrell, 2008). In addition, further disparity exists *between* POC racial and ethnic groups, with Indigenous people and Asian Americans having the least representation in scientific literature for standard treatment outcomes (Carter et al., 2012; Jackson et al., 2006; Liu et al., 2019). To our knowledge, there is only one report to date (Markell et al., 2014) of EBPT for social anxiety or generalized anxiety disorder (GAD) in Black individuals. This disparity of evidence is important given the associations between racism, discrimination, and increased risk for mental health difficulties (Williams, 2018), such as social anxiety disorder (SOC) (Levine et al., 2014).

Research has produced mixed findings on primary outcomes of symptoms of anxiety, depression, and traumatic stress, and also on rates of attrition in POC (Carter et al., 2012; Horrell, 2008). Some early studies found no differences in PTSD outcomes and attrition among Black, Latinx, and White veterans (Rosenheck and Fontana, 1996, 2002), and several CBT studies reported no differences between White women and women of color (specifically Black and Asian American/Pacific Islander women) on treatment outcomes or attrition for PTSD and obsessive-compulsive disorder (OCD) treatments (Friedman et al., 2003; Kubany et al., 2003; Zoellner et al., 1999). In addition, a more recent telephone-delivered CBT program for GAD and panic disorder found no differences in outcomes for Black patients (Rollman et al., 2017). However, other studies have found higher attrition in POC (Fortuna et al., 2010; Owen et al., 2012; Roberts et al., 2011; Spoont et al., 2015), and in some studies, this difference in attrition is present despite no differences in anxiety and depression outcomes (*e.g.*, treatment for PTSD in Black and White veterans, Rosenheck et al., 1995; CBT for PTSD in Black and White women, Lester et al., 2010). Other studies have reported both higher attrition *and* lower anxiety and depression symptom improvement for POC compared with White patients (CBT for panic disorder and agoraphobia in Black women, Chambless and Williams, 1995; Friedman and Paradis, 1991; CBT for depression in low-income Black and Latinx individuals, Organista et al., 1994); yet, recent studies have found that Black veterans receiving PTSD treatment may have *lower* attrition rates (Maguen et al., 2019) but worse outcomes (Sripada et al., 2019) than non-Black veterans. Overall, the very limited research on EBPTs that report attrition and treatment outcomes by race and ethnicity is inconsistent, and this work has, in general, failed to include Latinx, Asian American, or Indigenous people. In sum, EBPTs for common mental health disorders have not been sufficiently tested with POC; thus, evidence that EBPTs are efficacious and effective for Black, Indigenous, Asian American, and Latinx people has yet to be well established.

Current Study

The present study reports data from a large randomized controlled efficacy trial that compared two styles of CBT, transdiagnostic and single-disorder CBT, for anxiety and comorbid depressive disorders. In line with the NIH amendment (NIH, 2017), our analyses examine outcomes by race and ethnicity in this clinical trial. For the purposes of this post hoc investigation, the authors aim to compare treatment retention and symptom outcomes for White and POC study participants. Based on the findings of previous similar post hoc studies (*e.g.*, Lester et al., 2010), we hypothesize that no observable differences will be found across groups in outcomes for symptoms of anxiety and depression. However, given the variability in findings on treatment retention and that study protocols did not include targeted strategies to retain POC participants (Yancey et al., 2006), we hypothesize higher treatment dropout rates for POC participants compared with White patients. In addition, an exploratory aim of this study is to examine treatment effect size across time points for the three largest POC groups in this study (Black, Asian

American, and Latinx participants) to clarify whether treatment may have been less efficacious for any particular group.

METHOD

Participants

Data were derived from a study examining transdiagnostic and single-diagnosis CBTs, described in detail in Barlow et al. (2017). Participants were enrolled in a clinical trial completed at an outpatient clinic at a large urban university. Individuals were included in the study if they were 18 years or older, fluent in English, able to attend all treatment sessions and assessments, and met criteria for a principal (most interfering and distressing) *Diagnostic and Statistical Manual of Mental Disorders* (*DSM*) diagnosis of any of the following: GAD, OCD, SOC, or panic disorder, with or without agoraphobia (PD/A). Exclusion criteria included diagnoses or psychological conditions that warranted immediate or simultaneous treatment (*e.g.*, active psychosis, organic mental disorder, high suicide risk, and acute substance use disorder) or a recent course of CBT (*i.e.*, eight or more sessions within the past 5 years). If participants endorsed regularly taking any psychotropic medications during eligibility screening, they were asked to remain stable on their medication dosage for the duration of treatment and to report any medication changes to study personnel.

Information on race and ethnicity was collected from a study demographics form (see description of form in Measures section). Participants self-reported race by selecting one or more of the following: (a) *American Indian or Alaska Native*, (b) *Asian,* (c) *Native Hawaiian or other Pacific Islander*, (d) *Black or African American*, (e) *White/Caucasian*, (f) *more than one race*, (g) *unknown or not reported* or by writing in their identification. In addition, participants were asked to self-report between three categories for ethnicity: *Hispanic or Latino, Non-Hispanic or Latino*, or *Unknown*. These categories were listed on the demographics form in accordance with reporting policy from NIH (2001).

As shown in Table 1, the mean age of White participants ($n = 136$, 52.9% female) was 31.04 years (SD = 11.05 years). The mean age of POC participants ($n = 43$, 62.8% female) was 29.4 years (SD = 9.9 years). Participants in the POC sample identified as *Black or African American* ($n = 13$), *Asian* ($n = 12$), and *Hispanic or Latino* ($n = 15$, 13 of which identified as both *White/Caucasian* and *Hispanic or Latino*, *Native Hawaiian or other Pacific Islander* ($n = 1$), and *more than one race* ($n = 4$).

Procedures

Written informed consent was obtained from participants before participation. Participants were randomized by principal diagnosis to receive either a transdiagnostic CBT intervention or a CBT intervention matched to their principal diagnosis, or to a waitlist control. For the purposes of this investigation, clinical outcomes from both CBT treatments were examined together, and waitlist participants were excluded. Outcomes were not compared between treatment groups or to the waitlist because the sample size of POC participants when divided by study condition would be too small to allow for comparison. CBT treatment lasted 16 sessions, except for those with a principal diagnosis of PD/A, who received 12 sessions, in line with recommendations from protocol developers (Barlow and Craske, 2007). Participants' symptoms were assessed at baseline, every four sessions, and at posttreatment. In the case of comorbid diagnoses, principal diagnosis was determined by team consensus. All participants in the treatment condition were also assessed 6 and 12 months after the study. They were administered a battery of clinician-rated assessment for each clinical diagnosis they were assigned at baseline (for further details, see Barlow et al., 2017).

The study's clinical team (*i.e.*, assessors and therapists) was composed of clinical psychology doctoral students with 2 to 4 years,

TABLE 1. Baseline Demographic Characteristics for Treatment Sample

	POC (*n* = 43), Count (%)	White (*n* = 136), Count (%)
Age, mean (SD)	29.4 (9.9)	31.0 (11.0)
Sex		
Women	27 (62.8)	72 (52.9)
Men	16 (37.2)	64 (47.1)
Ethnicity/race		
Asian American	12 (27.9)	
Black/African American	13 (30.2)	
Hispanic/Latinx	15 (34.9)	
More than one race	4 (9.3)	
Native Hawaiian/other Pacific Islander	1 (2.3)	
White/European American		136 (100)
Marital status		
Married or cohabitating	8 (18.6)	41 (30.1)
Single	34 (79.1)	81 (59.6)
Divorced or separated	1 (2.3)	6 (4.4)
Education		
Elementary		4 (2.9)
High school	4 (9.3)	7 (5.1)
College	25 (58.2)	81 (59.6)
Advanced degree	14 (32.7)	38 (27.9)
Current psychotropic medication	17 (39.5)	83 (61.0)
Principal diagnosis		
OCD	5 (11.6)	30 (22.1)
GAD	12 (27.9)	37 (27.2)
Panic disorder with/without agoraphobia	6 (14.0)	41 (30.1)
SOC	20 (46.5)	28 (20.6)
Comorbid diagnoses	37 (86.1)	113 (83.1)
No. diagnoses, mean (SD)	2.56 (2.0)	2.18 (1.8)

postdoctoral fellows with 5 to 6 years, and licensed clinical psychologists with 10 or more years of clinical experience. Assessors included one man and five women, and therapists included two men and five women. All assessors and therapists were White. Study assessors completed initial training procedures, then were selected at random to submit audiotaped assessments for rating by a second evaluator throughout the trial to ensure interrater reliability. Interrater agreement for principal diagnosis clinical severity rating (CSR) was 98%. In addition, 20% of study therapists' audiotaped treatment sessions were selected at random for adherence and competence ratings to ensure treatment fidelity across conditions. Tapes were rated by an external team of expert raters associated with the development of each treatment protocol, and they used standardized assessment ratings. Fidelity scores across protocols were good to excellent.

Measures

The measures used for the current investigation are primary outcomes of the main study. Hereinafter, we specify clinical cut-off scores and the psychometric properties of the measures, if any were found, for POC. For full details on measures' psychometric properties, see Barlow et al. (2017).

Anxiety Disorders Interview Schedule

Participants were assessed for current anxiety, mood, trauma-related, OCD-related, and somatic symptom disorders with an Anxiety Disorders Interview Schedule (ADIS) (Di Nardo et al., 1994; Brown and Barlow, 2014), a semistructured diagnostic clinical interview with CSR on a scale from *no symptoms* (0) to *extremely severe symptoms* (8), with a rating of 4 or above (*definitely disturbing/disabling*) indicating clinical levels of distress and interference. The ADIS has strong interrater reliability; however, no psychometric data on the ADIS have been published at the time of this writing.

Because the *DSM* (Fifth Edition) (*DSM-5*) (American Psychiatric Association, 2013) was published during the trial's data collection period, approximately two-thirds of the sample was assigned diagnoses based on the *DSM* (Fourth Edition) (*DSM-IV*) (American Psychiatric Association, 1994) criteria, and approximately one-third received diagnoses based on *DSM-5* criteria. To account for the *DSM-5's* separation of panic disorder and agoraphobia, and to standardize CSR assignments between the manuals, participants receiving panic disorder and/or agoraphobia diagnoses using *DSM-5* were given an additional overall PD/A CSR rating.

Panic Disorder Severity Scale

The Panic Disorder Severity Scale (PDSS) (Shear et al., 1997) was administered by study evaluators to measure panic disorder symptoms and their impact on participants' functional impairment. This clinician-rated measure consists of seven items that fall on a 5-point Likert-scale (0–4), with higher scores indicating higher symptom severity and impairment. A clinical cut-off score of 8 has been indicated for PDSS, and 40% to 74% improvement in scores indicates "much improved" (Furukawa et al., 2009). To the authors' knowledge, no data were available on the psychometric properties of this measure for POC samples.

Liebowitz Social Anxiety Scale

Study evaluators administered the Liebowitz Social Anxiety Scale (LSAS), a 24-item, clinician-rated scale, which measures both avoidance and fear of social interactions and performances, with higher scores indicating higher severity (Fresco et al., 2001; Heimberg et al., 1999; Liebowitz, 1987). A clinical cut-off of a total score of 60 (sum of the two subscales fear and avoidance) has been found in some studies (Mennin et al., 2002). The LSAS has shown excellent internal consistency and temporal stability for Black patients (Beard et al., 2011) and Latinx patients (Beard et al., 2012), suggesting the measure may perform similarly for Black, Latinx, and White samples.

GAD Severity Scale

The GAD Severity Scale (GADSS) (Shear et al., 2006) evaluates core symptoms of GAD and their impact on an individual's functioning. The GADSS is a 6-item, clinician-rated measure with higher scores indicating higher symptom severity and functional impairment; items fall on a 5-point scale, ranging from *none* (0) to *very severe* (4). To the authors' knowledge, no data were available on the psychometric properties of this measure for POC samples. One study evaluating the utility of the GADSS in older adult populations included 22% Black individuals and found that the measure demonstrated adequate internal consistency, strong interrater reliability, adequate convergent validity, poor diagnostic accuracy, and mixed discriminant validity (Weiss et al., 2009); however, such properties were not broken down by ethnicity.

Yale-Brown Obsessive-Compulsive Scale Interview, Second Edition

The Yale-Brown Obsessive-Compulsive Scale Interview, Second Edition (Y-BOCS-II) is a 10-item, clinician-rated interview designed to

assess severity of OCD symptoms and resulting functional impairment (Goodman et al., 1989; Storch et al., 2010; Wu et al., 2016). Higher scores are indicative of higher severity of OCD and impairment, and items are scored from *none* (0) to *extreme* (5) on a Likert scale. Studies of criterion validity have shown a clinical cut-off score of 13, which indicates clinical levels of OCD (Storch et al., 2015). In addition, the Y-BOCS clinician-rated version has demonstrated concurrent validity across Black adults (Williams et al., 2013b) and Black, Latinx, South Asian/East Indian, and Southeast Asian undergraduates (Washington et al., 2008).

Structured Interview Guide for the Hamilton Anxiety Rating Scale

The Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) (Shear et al., 2001) is a 14-item, clinician-rated interview guide that was developed to provide specific instructions for administration and scoring of the Hamilton Rating Scale for Anxiety (Hamilton, 1959). To the authors' knowledge, no data were available on the psychometric properties of this measure for POC samples.

Structured Interview Guide for the Hamilton Depression Rating Scale

The Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) (Williams, 1988) is a 17-item, clinician-rated interview guide that was developed to provide specific instructions for administration and scoring of the Hamilton Rating Scale for Depression (Hamilton, 1960). To the authors' knowledge, no data were available on the psychometric properties of this measure for POC samples.

Demographics Form

Study participants provided detailed demographic information regarding race and ethnicity, sex, age, household income, marital status, employment, and education. Sex was assessed as a binary variable (man or woman). Age and household income were continuous variables. Similar to other studies (*e.g.*, DeRubeis et al., 2014) marital status was defined as married or cohabitating *vs.* single. Employment was divided into three categories: unemployed, full-time student, or employed (including *full-time*, *part-time*, and "*other*" employment). Finally, education was defined as high school (including individuals whose highest level of education was some or the completion of high school), college (some college, associate's degree, or bachelor's degree), and advanced degree (master's degree, doctoral student, doctorate, other [*e.g.*, JD]).

Treatment

Study participants received CBT based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2018) or a single-diagnosis protocol (SDP). The UP targeted core temperamental factors that are thought to lead to the development and maintenance of anxiety, depression, and related disorders; it has demonstrated good efficacy compared with SDPs (Barlow et al., 2017). SDPs included in this trial targeted SOC (Hope et al., 2006), PD/A (Barlow and Craske, 2007), GAD (Zinbarg et al., 2006), and OCD (Foa et al., 2012). For full details on treatments, see Barlow et al. (2017).

RESULTS

Analyses were conducted using SPSS versions 20 and 27. Data from both CBT conditions were collapsed to compare the effects of treatment on POC and White participants posttreatment as well as at 6- and 12-month follow-up. Missing data were imputed at the item level when 30% or fewer of the items on a given scale were unanswered by substituting the mean of a participant's responses for missing values (Ake, 2005; Fox-Wasylyshyn and El-Masri, 2005; Roth et al., 1999). Listwise deletion was used when more than 30% of the items were missing. In addition, Shapiro-Wilk tests indicated that the data were normally distributed with the following exceptions: SIGH-D posttreatment ($p = 0.001$), LSAS Avoidance ($p = 0.04$), SIGH-A ($p = 0.016$), and SIGH-D ($p = 0.015$) at 6-month follow-up, and SIGH-D ($p = 0.022$) at 12-month follow-up. For all of these measures, the data were significantly positively skewed.

Pretreatment

Preliminary Analyses and Symptom Differences at Baseline

Differences between White participants and POC on several baseline variables were explored. χ^2 test indicated no difference between these groups on the following demographic variables: sex, $\chi^2(1) = 1.28$, $p = 0.26$; employment, $\chi^2(5) = 2.48$, $p = 0.77$; education, $\chi^2(8) = 4.01$, $p = 0.85$; marital status, $\chi^2(1) = 2.19$, $p = 0.14$; and treatment condition, $\chi^2(1) = 2.10$, $p = 0.15$. In addition, independent samples t tests found no difference in age, $t(177) = -0.85$, $p = 0.40$, or household income, $t(152) = -1.68$, $p = 0.09$.

Regarding clinical characteristics at baseline, the most common principal diagnosis for POC was SOC ($n = 20$), and the average ADIS CSR across all principal diagnoses fell in the *moderate* to *severe* impairment range ($M = 5.5$, SD = 0.8), with an average of 2.6 comorbid diagnoses (SD = 2.0). When compared, independent samples t tests showed no difference between POC and White participants on principal diagnosis CSR, $t(177) = 0.68$, $p = 0.50$; number of comorbid diagnoses, $t(177) = 0.61$, $p = 0.54$; GADSS, $t(85) = 1.00$, $p = 0.32$; PDSS, $t(53) = 0.83$, $p = 0.41$; LSAS total fear, $t(91) = 1.71$, $p = 0.09$; LSAS total avoidance, $t(91) = 1.53$, $p = 0.13$; SIGH-D, $t(177) = 0.81$, $p = 0.42$; SIGH-A, $t(177) = 0.51$, $p = 0.61$; and Y-BOCS, $t(47) = 0.15$, $p = 0.88$.

However, χ^2 tests revealed that POC and White participants differed on use of medication for psychological disorders at baseline, $\chi^2(1) = 7.22$, $p = 0.007$, and their principal diagnosis, $\chi^2(3) = 13.27$, $p = 0.004$. Although 42.9% of the overall sample was currently taking a psychoactive medication, a lower percentage of POCs (39.5%) were taking medications compared with White participants (61.0%). A Cramer's V value of 0.20 ($p = 0.007$) indicated that this association represented a weak positive relationship. With regard to principal diagnosis, an examination of adjusted residuals indicated significantly more POCs were diagnosed with SOC and significantly fewer POCs were diagnosed with PD/A. Furthermore, a Cramer's V value of 0.27 ($p = 0.004$) indicated a weak positive relationship.

Treatment Outcomes

Relationship Between Race or Ethnicity and Treatment Outcomes

Descriptive statistics for measures at each time point are displayed in Table 2. A χ^2 test indicated that there were no observable differences in rates of attrition between the two participant samples at posttreatment, $\chi^2(1) = 0.23$, $p = 0.63$. One-way ANCOVA analyses were conducted to examine differences in treatment outcomes at the post- and follow-up assessments between participant groups while controlling for continuous and categorical covariates. The presence of psychoactive medications and principal diagnosis were controlled in the analyses because these variables significantly differed between participant groups. Baseline scores of each measure were also controlled in the analyses to account for symptom severity. Although some measures were not normally distributed, correlations between baseline and the measure of interest ranged from 0.30 to 0.46, and some have suggested that ANCOVA can still be appropriately used under these conditions (Vickers, 2005).

Levene's test indicated equal variance on all measures between the two groups at all time points (all p values >0.05). Results of the ANCOVA suggested that there was a significant difference in posttreatment SIGH-A scores, $F(1,114) = 4.52$, $p = 0.04$, $\eta^2 = 0.04$. A

TABLE 2. Descriptive Statistics at Each Time Point for Clinician-Rated Measures

	Pretreatment				Posttreatment				12MFU			
	POC		White		POC		White		POC		White	
Measure	n	M (SD)	n	M (SD)	n	M (SD)	n	M (SD)	n	M (SD)	n	M (SD)
CSR	43	5.53 (0.83)	136	5.44 (0.78)	30	3.03 (1.71)	90	2.96 (1.56)	33	2.52 (1.73)	85	2.65 (1.65)
PDSS	11	14.73 (4.94)	44	13.52 (4.16)	6	7.00 (5.18)	32	6.53 (4.18)	6	5.50 (6.16)	22	5.55 (5.08)
GADSS	22	14.23 (3.61)	65	13.43 (2.09)	15	7.33 (4.52)	44	7.80 (3.51)	14	6.69 (4.93)	43	9.14 (4.31)
LSAS Fear	29	39.41 (13.91)	64	34.36 (12.87)	24	22.83 (12.22)	41	20.49 (11.81)	24	23.21 (13.57)	46	20.46 (11.59)
LSAS Avoidance	29	34.70 (17.92)	64	29.59 (13.38)	24	14.96 (10.89)	41	14.46 (12.16)	24	17.08 (13.43)	46	14.72 (12.10)
Y-BOCS-II	9	27.33 (8.37)	40	26.95 (6.82)	8	13.75 (9.98)	24	16.67 (6.18)	6	10.67 (8.82)	19	14.32 (8.79)
SIGH-D	43	12.23 (7.54)	136	11.52 (6.68)	30	5.92 (4.72)	90	7.10 (5.30)	32	5.16 (4.00)	84	6.84 (6.33)
SIGH-A	43	17.65 (10.50)	136	16.84 (8.58)	30	7.07 (5.51)	90	9.55 (6.46)	32	6.66 (5.83)	84	9.61 (8.63)

Posttreatment for the PDSS used week 12 data given the fact that participants with a principal diagnosis of panic disorder completed a 12-session protocol.

comparison of the estimated marginal means indicated that POC had lower SIGH-A scores at posttreatment ($M = 6.90$, SE $= 1.10$) than White participants had ($M = 9.64$, SE $= 0.63$). No significant differences were found at posttreatment between White participants and POC on any of the remaining measures, including the principal diagnosis CSR, PDSS, GADSS, LSAS, Y-BOCS, and SIGH-D (Table 2). Similarly, as shown in Table 2, no observable differences were found between the two groups on any of the outcome variables at either 6-month follow-up (MFU) and 12MFU.

Examination of Effect Sizes by Racial and Ethnic Group

An exploratory aim of this study was to further examine differences in treatment response among White participants and POC from different racial and ethnic groups. Analyses focused on the effect sizes of treatment outcomes of White participants and the three groups of POC with comparable sample sizes: Black, Asian American, and Latinx participants. The SIGH-A and SIGH-D (see means and standard deviations in Table 3) were used for these analyses because all participants received these measures regardless of principal diagnosis. Within-group standardized gain effect sizes were calculated and compared at posttreatment and follow-up (Table 4). At posttreatment, the largest significant effect sizes for anxiety were found with Black participants (SIGH-A $ESsg = 1.29$), followed by Latinx participants (SIGH-A $ESsg = 0.99$), White participants (SIGH-A $ESsg = 0.72$), and then Asian American participants (SIGH-A $ESsg = 0.68$).

Similarly, the largest significant effect sizes for depression were found with Black participants (SIGH-D $ESsg = 1.24$), followed by Latinx participants (SIGH-D $ESsg = 0.97$) and then White participants (SIGH-D $ESsg = 0.55$). However, the effect size for depression with Asian American participants was nonsignificant at posttreatment. By the 12-month follow-up point, all effect sizes across all groups for anxiety and depression were significant and moderate to large (Table 4).

DISCUSSION

This study adds to the limited literature on treatment outcomes of standard EBPTs for anxiety, depression, and other common mental health disorders in POC. Post hoc analyses were used to examine treatment outcomes between POC and White study participants from a large randomized controlled trial of CBT protocols. As hypothesized, results from the present study evidenced no observable differences in symptoms of anxiety and depression between POC and White participants. Contrary to our hypothesis, there were also no observable differences in the rates of attrition between White participants and POC. Lastly, our exploratory analyses provided data on within-group treatment effect sizes for Black, Latinx, Asian American, and White participants.

At baseline, the POC and White participants demonstrated no differences on demographic and clinical characteristics with the exceptions of principal diagnoses and use of psychotropic medications. POCs were more likely to have a principal diagnosis of SOC and less likely to be on medications or have a principal diagnosis of panic disorder. Lower rates of medication for psychological conditions in POC compared with White participants have been previously reported (Coleman et al., 2016; Jung et al., 2014) as have lower rates of panic disorder (Marques et al., 2011). Higher rates of social anxiety for POC participants are unsurprising given research on the effects of discrimination and racism on social anxiety in Black individuals (Levine et al., 2014), as well as findings that Asian Americans, who are more likely to be culturally socialized toward interdependent self-construal and experience heightened sensitivity to social threat, score higher on measures of social anxiety (Krieg and Xu, 2018).

As hypothesized, treatment outcome differences were not observed for symptoms of anxiety and depression between White participants and POC. One exception to this was a better outcome for POC on one measure of anxiety at posttreatment only; however, no differences on any measure were found between groups on outcomes 6- and 12 months after treatment. Although some studies have found lower improvement rates for Black and Latinx individuals with anxiety and depression (*e.g.*, Chambless and Williams, 1995; Friedman and Paradis, 1991; Organista et al., 1994) and better outcomes for culturally adapted treatments compared with standard ones (Hall et al., 2016; Rathod et al., 2018), our findings support the review by Huey et al. (2014) on the effects of standard and culturally adapted psychological treatments for POC (total of 140 trials), which found that outcomes of POC were comparable to those of White individuals. In sum, our preliminary data suggest manualized CBT for anxiety and comorbid depression may be helpful for POCs, as their outcomes aligned with those from the main study that showed clinically meaningful changes with treatment (Barlow et al., 2017). At minimum, our study shows that EBPTs for anxiety were not iatrogenic for our POC subsample.

Our findings on attrition align with the those of Friedman et al. (2003), Kubany et al. (2003), Rosenheck and Fontana (1996, 2002), and Zoellner et al. (1999), in that we found no relationship between race or ethnicity and early treatment termination. Hypothesized reasons for high attrition rates among POC include limited cultural responsiveness of treatments or therapists delivering care (Whaley and Davis, 2007) and the intersecting factor of socioeconomic status, as individuals with lower incomes may have greater barriers to regular attendance (Wierzbicki and Pekarik, 1993). Indeed, of the participants who provided information on their income (81 White participants and 33 POC, including 10 Asian Americans, 8 Latinx, and 12 Black participants), POC had significantly lower mean income ($M = 35,894.18$,

TABLE 3. Means and SDs of SIGH-A and SIGH-D by Racial or Ethnic Group

Race or Ethnicity (n)	SIGH-A, M (SD)	SIGH-D, M (SD)
Pretreatment		
Asian American (n = 12)	16.33 (11.59)	12.67 (8.52)
Black/African American (n = 13)	18.62 (11.53)	12.08 (7.81)
Latinx (n = 15)	16.60 (9.20)	12.07 (7.48)
White/European American (n = 136)	16.84 (8.58)	11.29 (6.40)
More than one race (n = 4)	21.50 (9.47)	12.00 (4.90)
Native Hawaiian/Pacific Islander (n = 1)	13.00	16.00
Posttreatment		
Asian American (n = 7)	9.29 (5.22)	9.14 (5.55)
Black/African American (n = 9)	4.67 (3.87)	4.28 (2.58)
Latinx (n = 13)	7.38 (6.50)	5.62 (4.96)
White/European American (n = 90)	9.55 (6.46)	7.10 (5.30)
More than one race (n = 2)	10.50 (2.12)	7.50 (7.78)
Native Hawaiian/Pacific Islander (n = 1)	8.00	6.00
12MFU		
Asian American (n = 10)	5.10 (3.87)	5.30 (3.74)
Black/African American (n = 9)	6.67 (5.10)	5.33 (3.78)
Latinx (n = 12)	7.75 (7.79)	5.00 (4.81)
White/European American (n = 84)	9.61 (8.63)	6.84 (6.33)
More than one race (n = 2)	8.00 (1.41)	3.50 (0.71)
Native Hawaiian/Pacific Islander (n = 1)	3.00	4.00

Only one participant identified as Native Hawaiian/other Pacific Islander so no SD is available for this group. Two participants identified as Latinx and another underrepresented group and are counted in both categories.

SD = 25,017.22) compared with White participants, $t(112) = -2.3$, $p < 0.01$. Despite this income disparity, there was still no significant difference between groups in attrition; this finding provides preliminary support for CBT's potential to retain POC with anxiety and related disorders in treatment.

Finally, exploratory analyses revealed large, significant effect sizes on both anxiety and depression for Black and Latinx participants, moderate, significant effect sizes on anxiety and depression for White participants with anxiety and depression, and moderate effect sizes on anxiety for Asian American participants at posttreatment and follow-up.

However, the effect size for depression with Asian American participants was nonsignificant at posttreatment and significant 1 year later. These findings parallel extant reviews of CBT for POC; despite some studies showing preliminary efficacy for CBT on depression in Black and Latinx individuals, historically, it has been difficult to draw similar conclusions for Asian Americans, because Asian Americans have been so underrepresented in CBT research (Horrell, 2008; Huey and Tilley, 2018). One study found that culturally adapted CBT may be more effective than standard CBT in reducing Asian Americans' symptoms, although in this study, neither treatment achieved remission of severe depression (Hwang et al., 2015). Ultimately, more research is needed to determine whether Asian Americans benefit similarly to other groups from standard CBT.

Limitations

Findings from the present study should be understood within their limitations, many of which are not unique to our analyses but endemic to the research in this area. First, the present study was conducted post hoc, increasing the chances of a type I error, where false effects may be found. In addition, although this study failed to reject the null hypothesis of no differences between groups, not finding an effect is not the same as proving the effect does not exist and does not necessarily mean effects between groups are equivalent.

Another important limitation of the study is the measurement of symptoms. Some assessment measures used in the study had been validated with POC populations but others have not. Psychological measures may display different psychometric properties for different populations than the original one with which a measure was developed and calibrated (Dana, 1993; Hambrick et al., 2010); consequently, we cannot be certain that outcomes for POC can be interpreted the same as outcomes for White participants. Our study also reports clinician-administered measures; of note, all study clinicians were White, and their ratings of POC may have been influenced by their level of cultural responsiveness and/or participants' comfort with disclosing fear and perceived threat related to their marginalized status (Hunter and Schmidt, 2010).

Possibly the greatest limitation of the study is that all POCs were grouped into a single, heterogeneous category for the purpose of conducting primary analyses. Black, Latinx, and Asian American individuals can strongly differ in terms of cultural values, immigration experiences and acculturation, specific minority stressors, and language; grouping them together may obscure meaningful differences among members of these groups. Furthermore, each subgroup may vary in their treatment response, and this study would be unable to detect these nuances in primary analyses (Miranda et al., 2003). Unfortunately, although the subsamples of POC were mostly representative of the state in which the research took place, each subgroup was too small to

TABLE 4. Within-Condition Effect Sizes for CBT by Racial or Ethnic Group

Measure	Race or Ethnicity	n	ESsg (95% CI) BL-Post	n	ESsg (95% CI) BL-12MFU
SIGH-A	White/European American	90	−0.72* (−0.92 to −0.52)	84	−0.77* (−1.43 to −0.10)
	Black/African American	9	−1.29* (−2.28 to −0.31)	9	−0.92* (−1.58 to −0.26)
	Latinx	13	−0.99* (−1.62 to −0.36)	12	−1.04* (−1.94 to −0.14)
	Asian American	7	−0.68* (−1.29 to −0.08)	10	−1.31* (−2.27 to −0.35)
SIGH-D	White/European American	90	−0.55* (−0.74 to −0.36)	84	−0.73* (−0.99 to −0.47)
	Black/African American	9	−1.24* (−2.22 to −0.26)	9	−0.83* (−1.54 to −0.13)
	Latinx	13	−0.97* (−1.59 to −0.34)	12	−1.40* (−2.35 to −0.44)
	Asian American	7	−0.71 (−1.69 to 0.28)	10	−1.05* (−2.06 to −0.04)

*$p < 0.05$.
BL indicates baseline; ES, effect size.

analyze in the primary analyses independently. Because we were unable to recruit any Indigenous participants, our study cannot contribute to the body of knowledge on CBT for Indigenous people. We also have incomplete racial data for individuals who were ultimately ineligible for the study.

Finally, we did not have available data on the degree to which POC affiliated with their culture or with the cultural variables that are predominant in CBT (Hays, 2009), and so race and ethnicity were used as a limited proxy for culture. Our sample comprised individuals seeking specialized care at a single treatment center, who may overall differ in socioeconomic status from those visiting community mental health centers; similarly, we did not have data on immigration status, and participants who did not speak English were excluded from the trial. These variables may be important in moderating treatment responses for POC and may limit the generalizability of our findings. However, within these limitations, the present study makes a significant contribution to the literature on treatment and attrition outcomes of POC receiving CBT for anxiety, depression, and related disorders, given the high methodological rigor of the broader CBT trial and the paucity of research in this area.

Future Directions

Future studies examining the treatment outcomes of POC would benefit from more stringent a priori methodology. More research is needed to validate psychometric properties of common symptom measures in POC, so that researchers using these measures can draw firmer conclusions about symptom outcomes; alternatively, measures that have been validated within a wide range of racial, ethnic, and cultural groups should be prioritized for use in clinical trials. In addition, studies should increase the enrollment of POC to be sufficiently powered to look at differences through more sophisticated statistical analyses such as noninferiority or equivalence analyses. It is important that trials are designed to strengthen the conclusions we can draw for how well treatments are working for different populations. Furthermore, treatment outcome studies must deliberately plan to examine treatment effectiveness for various sections of the population, not only White patients. More inclusive study recruitment and design would strengthen this field of study; given the multitude of barriers for POC in using treatment and/or participating in research studies, clinical researchers can attempt to improve recruitment of POC by cultivating trust and partnership with community health centers and organizations, being thorough and inclusive of family members in informed consent procedures, and diversifying their own research teams (George et al., 2014).

Additional research on the effectiveness of standard EBPTs may also guide cultural adaptation efforts (Fuchs et al., 2013; Lau, 2006) by clarifying which groups are well served by standard EBPTs and which groups can benefit from culturally specific adaptation. Part of this work also requires understanding the impact of historic and continued discrimination against POC in clinical science and practice. The effects of racism and discrimination on attitudes toward research, medical care, and mental health care are well documented (Freimuth et al., 2001; George et al., 2014): POCs are more likely to distrust mental health professionals (Thompson et al., 2004) and hesitate to participate in research studies (Williams et al., 2013a, 2013b). Variables related to the impact of racism or discrimination were not measured in the current study, and future research should more closely study the role of racism and discrimination on treatment outcomes and attrition.

CONCLUSION

The present study contributes to the very limited literature on the efficacy of standard EBPTs for POC. We examined treatment retention and symptom outcomes of POC compared with White participants in a randomized controlled trial of CBT for anxiety and comorbid depression. Overall, differences were not observed between groups on treatment attrition or outcomes, and moderate to large effect sizes on anxiety and depression were found at posttreatment for Black, Latinx, Asian American, and White participants, with the exception of depression for Asian Americans. Our findings indicate that standard EBPTs may work to alleviate symptoms of anxiety and depression for POC, and more research is needed to replicate these results. In addition, future research on standard EBPTs must focus on recruiting and retaining POC to more conclusively determine treatment efficacy for all racial and ethnic groups.

REFERENCES

Ake CF (2005) Rounding after multiple imputation with non-binary categorical covariates. In *Proceedings of the thirtieth annual SAS® users group international conference* (pp 1–11). Cary, NC: SAS Institute Inc.

American Psychiatric Association (1994) *Diagnostic and statistical manual of mental disorders* (4th ed). Washington, DC: APA.

American Psychiatric Association (2013) *Diagnostic and statistical manual of mental disorders* (5th ed). Washington, DC: APA.

Barlow DH, Craske MG (2007) *Mastery of your anxiety and panic: Therapist guide* (4th ed). New York, NY: Oxford University Press.

Barlow DH, Farchione TJ, Bullis JR, Gallagher MW, Murray-Latin H, Sauer-Zavala S, Bentley KH, Thompson-Hollands J, Conklin LR, Boswell JF, Ametaj AA, Carl JR, Boettcher HT, Cassiello-Robbins C (2017) The Unified Protocol for transdiagnostic

treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: A randomized clinical trial. *JAMA Psychiat*. 74:875–884.

Barlow DH, Sauer-Zavala S, Farchione TJ, Murray Latin H, Ellard KK, Bullis JR, Bentley KH, Boettcher HT, Cassiello-Robbins C (2018) *Unified Protocol for the transdiagnostic treatment of emotional disorders: Patient workbook* (2nd ed). New York, NY: Oxford University Press.

Beard C, Rodriguez BF, Moitra E, Sibrava NJ, Bjornsson A, Weisberg RB, Keller MB (2011) Psychometric properties of the Liebowitz Social Anxiety Scale (LSAS) in a longitudinal study of African Americans with anxiety disorders. *J Anxiety Disord*. 25:722–726.

Beard C, Rodriguez BF, Weisberg RB, Perry A, Keller MB (2012) Psychometric properties of the Liebowitz Social Anxiety Scale in a longitudinal study of Latinos with anxiety disorders. *Hisp J Behav Sci*. 34:269–278.

Benuto LT, Bennett NM, Casas JB (2020) Minority participation in randomized controlled trials for prolonged exposure therapy: A systematic review of the literature. *J Trauma Stress*. 33:420–431.

Brown TA, Barlow DH (2014) *Anxiety and related disorders interview schedule for DSM-5—Lifetime Version*. New York, NY: Oxford University Press.

Carter MM, Mitchell FE, Sbrocco T (2012) Treating ethnic minority adults with anxiety disorders: Current status and future recommendations. *J Anxiety Disord*. 26: 488–501.

Carter MM, Sbrocco T (2018) Cognitive behavioral models, measures, and treatments for anxiety disorders in African Americans. In Chang EC, Downey CA, Hirsch JK, Yu EA (Eds), *Treating depression, anxiety, and stress in ethnic and racial groups: Cognitive behavioral approaches* (pp 179–202). American Psychological Association.

Chambless DL, Williams KE (1995) A preliminary study of African Americans with agoraphobia: Symptom severity and outcome of treatment with in vivo exposure. *Behav Ther*. 26:501–515.

Coleman KJ, Stewart C, Waitzfelder BE, Zeber JE, Morales LS, Ahmed AT, Ahmedani BK, Beck A, Copeland LA, Cummings JR, Hunkeler EM, Lindberg NM, Lynch F, Lu CY, Owen-Smith AA, Trinacty CM, Whitebird RR, Simon GE (2016) Racial-ethnic differences in psychiatric diagnoses and treatment across 11 health care systems in the mental health research network. *Psychiatr Serv*. 67: 749–757.

Cook BL, Zuvekas SH, Carson N, Wayne GF, Vesper A, McGuire TG (2014) Assessing racial/ethnic disparities in treatment across episodes of mental health care. *Health Serv Res*. 49:206–229.

Dana RH (1993) *Multicultural assessment perspectives for professional psychology*. Boston, MA: Allyn & Bacon.

David D, Cristea I, Hofmann SG (2018) Why cognitive behavioral therapy is the current gold standard of psychotherapy. *Front Psych*. 9:4.

De Luca SM, Blosnich JR, Hentschel EAW, King E, Amen S (2016) Mental health care utilization: How race, ethnicity and veteran status are associated with seeking help. *Community Ment Health J*. 52:174–179.

DeLuca SM, Kelman AR, Waelde LC (2018) A systematic review of ethnoracial representation and cultural adaptation of mindfulness-and meditation-based interventions. *Psychol Res*. 63:117–129.

DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L (2014) The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration. *PLoS One*. 9:e83875.

Di Nardo PA, Brown TA, Barlow DH (1994) *Anxiety disorders interview schedule for DSM-IV: Lifetime Version (ADIS-IV-L)*. New York, NY: Oxford University Press.

Foa EB, Yadin E, Lichner TK (2012) *Exposure and response (ritual) prevention for obsessive-compulsive disorder: Therapist guide* (2nd ed). New York, NY: Oxford University Press.

Fortuna LR, Alegria M, Gao S (2010) Retention in depression treatment among ethnic and racial minority groups in the United States. *Depress Anxiety*. 27:485–494.

Fox-Wasylyshyn SM, El-Masri MM (2005) Handling missing data in self-report measures. *Res Nurs Health*. 28:488–495.

Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T (2001) African Americans' views on research and the Tuskegee Syphilis Study. *Soc Sci Med*. 52:797–808.

Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D (2001) The Liebowitz Social Anxiety Scale: A comparison of the psychometric properties of self-report and clinician-administered formats. *Psychol Med*. 31: 1025–1035.

Friedman S, Paradis C (1991) African-American patients with panic disorder and agoraphobia. *J Anxiety Disord*. 5:35–41.

Friedman S, Smith LC, Halpern B, Levine C, Paradis C, Viswanathan R, Trappler B, Ackerman R (2003) Obsessive-compulsive disorder in a multi-ethnic urban outpatient clinic: Initial presentation and treatment outcome with exposure and ritual prevention. *Behav Ther*. 34:397–410.

Fuchs C, Lee JK, Roemer L, Orsillo SM (2013) Using mindfulness- and acceptance-based treatments with clients from nondominant cultural and/or marginalized backgrounds: Clinical considerations, meta-analysis findings, and introduction to the special series. *Cogn Behav Pract*. 20:1–12.

Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, Etschel E, Engel RR, Leucht S (2009) Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. *Depress Anxiety*. 26:922–929.

Geller SE, Koch A, Pellettieri B, Carnes M (2011) Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: Have we made progress? *J Womens Health (Larchmt)*. 20:315–320.

Geller SE, Koch AR, Roesch P, Filut A, Hallgren E, Carnes M (2018) The more things change, the more they stay the same: A study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials. *Acad Med*. 93:630–635.

George S, Duran N, Norris K (2014) A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. *Am J Public Health*. 104:e16–e31.

Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch Gen Psychiatry*. 46:1006–1011.

Grau PP, Kusch MM, Williams MT, Loyo KT, Zhang X, Warner RC, Wetterneck CT (2022) A review of the inclusion of ethnoracial groups in empirically supported posttraumatic stress disorder treatment research. *Psychol Trauma*. 14:55–65.

Hall GCN, Ibaraki AY, Huang ER, Marti CN, Stice E (2016) A meta-analysis of cultural adaptations of psychological interventions. *Behav Ther*. 47:993–1014.

Hambrick JP, Rodebaugh TL, Balsis S, Woods CM, Mendez JL, Heimberg RG (2010) Cross-ethnic measurement equivalence of measures of depression, social anxiety, and worry. *Assessment*. 17:155–171.

Hamilton M (1959) The assessment of anxiety states by rating. *Br J Med Psychol*. 32: 50–55.

Hamilton M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 23:56–62.

Hays PA (2009) Integrating evidence-based practice, cognitive–behavior therapy, and multicultural therapy: Ten steps for culturally competent practice. *Prof Psychol Res Pract*. 40:354–360.

Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR (1999) Psychometric properties of the Liebowitz Social Anxiety Scale. *Psychol Med*. 29:199–212.

Hope DA, Heimberg RG, Turk CL (2006) *Managing social anxiety: A cognitive behavioral therapy approach*: *Therapist guide* (2nd ed). New York, NY: Oxford University Press.

Horrell SCV (2008) Effectiveness of cognitive-behavioral therapy with adult ethnic minority clients: A review. *Prof Psychol Res Pract*. 39:160–168.

Huey SJ Jr., Tilley JL (2018) Effects of mental health interventions with Asian Americans: A review and meta-analysis. *J Consult Clin Psychol*. 86:915–930.

Huey SJ Jr., Tilley JL, Jones EO, Smith CA (2014) The contribution of cultural competence to evidence-based care for ethnically diverse populations. *Annu Rev Clin Psychol*. 10:305–338.

Hunter LR, Schmidt NB (2010) Anxiety psychopathology in African American adults: Literature review and development of an empirically informed sociocultural model. *Psychol Bull.* 136:211–235.

Hwang WC, Myers HF, Chiu E, Mak E, Butner JE, Fujimoto K, Wood JJ, Miranda J (2015) Culturally adapted cognitive-behavioral therapy for Chinese Americans with depression: A randomized controlled trial. *Psychiatr Serv.* 66:1035–1042.

Jackson LC, Schmutzer PA, Wenzel A, Tyler JD (2006) Applicability of cognitive-behavior therapy with American Indian individuals. *Psychotherapy (Chic).* 43:506–517.

Jung K, Lim D, Shi Y (2014) Racial-ethnic disparities in use of antidepressants in private coverage: Implications for the affordable care act. *Psychiatr Serv.* 65:1140–1146.

Krieg A, Xu Y (2018) From self-construal to threat appraisal: Understanding cultural differences in social anxiety between Asian Americans and European Americans. *Cultur Divers Ethnic Minor Psychol.* 24:477–488.

Kubany ES, Hill EE, Owens JA (2003) Cognitive trauma therapy for battered women with PTSD: Preliminary findings. *J Trauma Stress.* 16:81–91.

Lau AS (2006) Making the case for selective and directed cultural adaptations of evidence-based treatments: Examples from parent training. *Clin Psychol Sci Pract.* 13:295–310.

Lester K, Artz C, Resick PA, Young-Xu Y (2010) Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. *J Consult Clin Psychol.* 78:480–489.

Levine DS, Himle JA, Abelson JM, Matusko N, Dhawan N, Taylor RJ (2014) Discrimination and social anxiety disorder among African-Americans, Caribbean Blacks, and non-Hispanic Whites. *J Nerv Ment Dis.* 202:224–230.

Liebowitz MR (1987) Social phobia. *Mod Probl Pharmacopsychiatry.* 22:141–173.

Lipson SK, Kern A, Eisenberg D, Breland-Noble AM (2018) Mental health disparities among college students of color. *J Adolesc Health.* 63:348–356.

Liu Y, Elliott A, Strelnick H, Aguilar-Gaxiola S, Cottler LB (2019) Asian Americans are less willing than other racial groups to participate in health research. *J Clin Transl Sci.* 3(2–3):90–96.

Maguen S, Li Y, Madden E, Seal KH, Neylan TC, Patterson OV, DuVall SL, Lujan C, Shiner B (2019) Factors associated with completing evidence-based psychotherapy for PTSD among veterans in a national healthcare system. *Psychiatry Res.* 274:112–128.

Markell HM, Newman MG, Gallop R, Gibbons MBC, Rickels K, Crits-Christoph P (2014) Combined medication and CBT for generalized anxiety disorder with African American participants: Reliability and validity of assessments and preliminary outcomes. *Behav Ther.* 45:495–506.

Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D (2011) Cross-cultural variations in the prevalence and presentation of anxiety disorders. *Expert Rev Neurother.* 11:313–322.

Mendoza DB, Williams MT, Chapman LK, Powers M (2012) Minority inclusion in randomized clinical trials of panic disorder. *J Anxiety Disord.* 26:574–582.

Mennin DS, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR (2002) Screening for social anxiety disorder in the clinical setting: Using the Liebowitz Social Anxiety Scale. *J Anxiety Disord.* 16:661–673.

Miranda J, Nakamura R, Bernal G (2003) Including ethnic minorities in mental health intervention research: A practical approach to a long-standing problem. *Cult Med Psychiatry.* 27:467–486.

National Institutes of Health (1993) National Institutes of Health Revitalization Act of 1993, 42 USC §289a *et seq.* (1993). Available at: https://orwh.od.nih.gov/sites/orwh/files/docs/NIH-Revitalization-Act-1993.pdf. Accessed August 16, 2022.

National Institutes of Health (2001) *NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research.* Available at: https://grants.nih.gov/policy/inclusion/women-and-minorities/guidelines.htm. Accessed August 16, 2022.

National Institutes of Health (2017) *Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research.* Available at: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-014.html. Accessed August 16, 2022.

Organista KC, Muñoz RF, González G (1994) Cognitive-behavioral therapy for depression in low-income and minority medical outpatients: Description of a program and exploratory analyses. *Cognit Ther Res.* 18:241–259.

Owen J, Imel Z, Adelson J, Rodolfa E (2012) 'No-show': Therapist racial/ethnic disparities in client unilateral termination. *J Couns Psychol.* 59:314–320.

Polo AJ, Makol BA, Castro AS, Colón-Quintana N, Wagstaff AE, Guo S (2019) Diversity in randomized clinical trials of depression: A 36-year review. *Clin Psychol Rev.* 67:22–35.

Rachman S (2009) Psychological treatment of anxiety: The evolution of behavior therapy and cognitive behavior therapy. *Annu Rev Clin Psychol.* 5:97–119.

Rathod S, Gega L, Degnan A, Pikard J, Khan T, Husain N, Munshi T, Naeem F (2018) The current status of culturally adapted mental health interventions: A practice-focused review of meta-analyses. *Neuropsychiatr Dis Treat.* 14:165–178.

Roberts AL, Gilman SE, Breslau J, Breslau N, Koenen KC (2011) Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. *Psychol Med.* 41:71–83.

Rollman BL, Belnap BH, Mazumdar S, Abebe KZ, Karp JF, Lenze EJ, Schulberg HC (2017) Telephone-delivered stepped collaborative care for treating anxiety in primary care: A randomized controlled trial. *J Gen Intern Med.* 32:245–255.

Rosenheck R, Fontana A (1996) Race and outcome of treatment for veterans suffering from PTSD. *J Trauma Stress.* 9:343–351.

Rosenheck R, Fontana A (2002) Black and Hispanic veterans in intensive VA treatment programs for posttraumatic stress disorder. *Med Care.* 40:I52–I61.

Rosenheck R, Fontana A, Cottrol C (1995) Effect of clinician-veteran racial pairing in the treatment of posttraumatic stress disorder. *Am J Psychiatry.* 152:555–563.

Roth PL, Switzer FS III, Switzer DM (1999) Missing data in multiple item scales: A Monte Carlo analysis of missing data techniques. *Organ Res Methods.* 2:211–232.

Sbrocco T, Carter MM, Lewis EL, Vaughn NA, Kalupa KL, King S, Suchday S, Osborn RL, Cintrón JA (2005) Church-based obesity treatment for African-American women improves adherence. *Ethn Dis.* 15:246–255.

Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL (2006) Generalized anxiety disorder severity scale (GADSS): A preliminary validation study. *Depress Anxiety.* 23:77–82.

Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA (1997) Multicenter collaborative panic disorder severity scale. *Am J Psychiatry.* 154:1571–1575.

Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, Pollack MH, Chandler L, Williams J, Ali A, Frank DM (2001) Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). *Depress Anxiety.* 13:166–178.

Spoont MR, Nelson DB, Murdoch M, Sayer NA, Nugent S, Rector T, Westermeyer J (2015) Are there racial/ethnic disparities in VA PTSD treatment retention? *Depress Anxiety.* 32:415–425.

Sripada RK, Blow FC, Rauch SAM, Ganoczy D, Hoff R, Harpaz-Rotem I, Bohnert KM (2019) Examining the nonresponse phenomenon: Factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. *J Anxiety Disord.* 63:18–25.

Storch EA, De Nadai AS, Conceição do Rosário M, Shavitt RG, Torres AR, Ferrão YA, Miguel EC, Lewin AB, Fontenelle LF (2015) Defining clinical severity in adults with obsessive-compulsive disorder. *Compr Psychiatry.* 63:30–35.

Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK (2010) Development and psychometric evaluation of the Yale–Brown Obsessive-Compulsive Scale—Second Edition. *Psychol Assess.* 22:223–232.

Thompson VLS, Bazile A, Akbar M (2004) African Americans' perceptions of psychotherapy and psychotherapists. *Prof Psychol Res Pract.* 35:19–26.

US Department of Health and Human Services (2001) *Mental health: Culture, race, and ethnicity—A supplement to mental health: A report of the surgeon general.* Available at: https://www.ncbi.nlm.nih.gov/books/NBK44243/. Accessed August 16, 2022.

Vespa J, Medina L, Armstrong DM (2018) US population projections: 2020–2060. Available at: https://www.census.gov/content/dam/Census/library/publications/2020/demo/p25-1144.pdf. Accessed August 16, 2022.

Vickers AJ (2005) Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. *BMC Med Res Methodol*. 5:35.

Washington CS, Norton PJ, Temple S (2008) Obsessive-compulsive symptoms and obsessive-compulsive disorder: A multiracial/ethnic analysis of a student population. *J Nerv Ment Dis*. 196:456–461.

Weiss BJ, Calleo J, Rhoades HM, Novy DM, Kunik ME, Lenze EJ, Stanley MA (2009) The utility of the Generalized Anxiety Disorder Severity Scale (GADSS) with older adults in primary care. *Depress Anxiety*. 26:E10–E15.

Whaley AL, Davis KE (2007) Cultural competence and evidence-based practice in mental health services: A complementary perspective. *Am Psychol*. 62:563–574.

Wierzbicki M, Pekarik G (1993) A meta-analysis of psychotherapy dropout. *Prof Psychol Res Pract*. 24:190–195.

Williams DR (2018) Stress and the mental health of populations of color: Advancing our understanding of race-related stressors. *J Health Soc Behav*. 59:466–485.

Williams JB (1988) A structured interview guide for the Hamilton Depression Rating Scale. *Arch Gen Psychiatry*. 45:742–747.

Williams MT, Beckmann-Mendez DA, Turkheimer E (2013a) Cultural barriers to African American participation in anxiety disorders research. *J Natl Med Assoc*. 105:33–41.

Williams MT, Wetterneck CT, Thibodeau MA, Duque G (2013b) Validation of the Yale-Brown Obsessive-Compulsive Severity Scale in African Americans with obsessive-compulsive disorder. *Psychiatry Res*. 209:214–221.

Wu MS, McGuire JF, Horng B, Storch EA (2016) Further psychometric properties of the Yale-Brown Obsessive Compulsive Scale—Second Edition. *Compr Psychiatry*. 66:96–103.

Yancey AK, Ortega AN, Kumanyika SK (2006) Effective recruitment and retention of minority research participants. *Annu Rev Public Health*. 27:1–28.

Yang KG, Rodgers CRR, Lee E, Lê Cook B (2020) Disparities in mental health care utilization and perceived need among Asian Americans: 2012–2016. *Psychiatr Serv*. 71:21–27.

Zinbarg RE, Craske MG, Barlow DH (2006) *Mastery of your anxiety and worry: Therapist guide* (2nd ed). New York, NY: Oxford University Press.

Zoellner LA, Feeny NC, Fitzgibbons LA, Foa EB (1999) Response of African American and Caucasian women to cognitive behavioral therapy for PTSD. *Behav Ther*. 30:581–595.